Vet Med - Czech, 2016, 61(8):467-473 | DOI: 10.17221/87/2016-VETMED

Successful response to imatinib in two dogs with inoperable grade III infiltrating mast cell tumours: a case reportCase Report

J.H. Kim1, H.J. Kim1, D.H. Kim2, J.H. Yim2, S.J. Lee2, K.H. Park2, H.Y. Yoon2
1 Konkuk University Veterinary Medical Teaching Hospital, Seoul, Republic of Korea
2 College of Veterinary Medicine, Konkuk University, Seoul, Republic of Korea

Two dogs were presented owing to sudden rapid growth of cutaneous masses greater than 10 cm on the neck and axillary region, respectively. Based on history and results of physical examinations, blood work, fine needle aspiration, histopathological examination, and computed tomography, inoperable grade III infiltrating mast cell tumours were diagnosed. After the initiation of imatinib treatment, the masses markedly shrank and became undetectable within 10 days in both dogs, although none of the tumour specimens showed evidence of mutations in sequencing of c-kit exons 8 and 11. These results suggest that imatinib could be a therapeutic option in patients with surgically inoperable canine mast cell tumours, even those that are histopathologically high grade without c-kit exon 8 or 11 mutations.

Keywords: canine; KIT; oncogene; target therapy; tyrosine kinase inhibitor

Published: August 31, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kim JH, Kim HJ, Kim DH, Yim JH, Lee SJ, Park KH, Yoon HY. Successful response to imatinib in two dogs with inoperable grade III infiltrating mast cell tumours: a case report. Vet Med - Czech. 2016;61(8):467-473. doi: 10.17221/87/2016-VETMED.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Antonescu CR, Besmer P, Guo T, Arkun K, Hom G, Koryotowski B, Leversha MA, Jeffrey PD, Desantis D, Singer S, Brennan MF, Maki RG, DeMatteo RP (2005): Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clinical Cancer Research 11, 4182-4190. Go to original source... Go to PubMed...
    2. Bonkobara M (2015): Dysregulation of tyrosine kinases and use of imatinib in small animal practice. Veterinary Journal 205, 180-188. Go to original source... Go to PubMed...
    3. Buchdunger E, O'Reilley T, Wood J (2002): Pharmacology of imatinib (STI571). European Journal of Cancer 38, S28-S36. Go to original source... Go to PubMed...
    4. Cooper M, Tsai X, Bennett P (2009): Combination CCNU and vinblastine chemotherapy for canine mast cell tumours: 57 cases. Veterinary and Comparative Oncology 7, 196-206. Go to original source... Go to PubMed...
    5. Downing S, Chien MB, Kass PH, Moore PF, London CA (2002): Prevalence and importance of internal tandem duplications in exons 11 and 12 of c-kit in mast cell tumors of dogs. American Journal of Veterinary Research 63, 1718-1723. Go to original source... Go to PubMed...
    6. Druker BJ, Lydon NB (2000): Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. The Journal of Clinical Investigation 105, 3-7. Go to original source... Go to PubMed...
    7. Galli SJ, Kitamura Y (1987): Genetically mast-cell-deficient W/Wv and Sl/Sld mice. Their value for the analysis of the roles of mast cells in biologic responses in vivo. The American Journal of Pathology 127, 191-198.
    8. Galli SJ, Zsebo KM, Geissler EN (1994): The kit ligand, stem cell factor. Advances in Immunology 55, 1-96. Go to original source... Go to PubMed...
    9. Gregory-Bryson E, Bartlett E, Kiupel M, Hayes S, YuzbasiyanGurkan V (2010): Canine and human gastrointestinal stromal tumors display similar mutations in c-KIT exon 11. BMC Cancer 10, 559. Go to original source... Go to PubMed...
    10. Hahn KA, Ogilvie G, Rusk T, Devauchelle P, Leblanc A, Legendre A, Powers B, Leventhal PS, Kinet JP, Palmerini F, Dubreuil P, Moussy A, Hermine O (2008): Masitinib is safe and effective for the treatment of canine mast cell tumors. Journal of Veterinary Internal Medicine 22, 1301-1309. Go to original source... Go to PubMed...
    11. Isotani M, Ishida N, Tominaga M, Tamura K, Yagihara H, Ochi S, Kato R, Kobayashi T, Fujita M, Fujino Y, Setoguchi A, Ono K, Washizu T, Bonkobara M (2008): Effect of tyrosine kinase inhibition by imatinib mesylate on mast cell tumors in dogs. Journal of Veterinary Internal Medicine 22, 985-988. Go to original source... Go to PubMed...
    12. Kobayashi M, Sugisaki O, Ishii N, Yamada O, Ito K, Kuroki S, Sasaki Y, Ono K, Washizu T, Bonkobara M (2012): Canine intestinal mast cell tumor with c-kit exon 8 mutation responsive to imatinib therapy. Veterinary Journal 193, 264-267. Go to original source... Go to PubMed...
    13. Kobie K, Kawabata M, Hioki K, Tanaka A, Matsuda H, Mori T, Maruo K (2007): The tyrosine kinase inhibitor imatinib [STI571] induces regression of xenografted canine mast cell tumors in SCID mice. Research in Veterinary Science 82, 239-241. Go to original source... Go to PubMed...
    14. Liao AT, Chien MB, Shenoy N, Mendel DB, McMahon G, Cherrington JM, London CA (2002): Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors. Blood 100, 585-593. Go to original source... Go to PubMed...
    15. London CA, Seguin B (2003): Mast cell tumors in the dog. The Veterinary Clinics of North America: Small Animal Practice 33, 473-489. Go to original source... Go to PubMed...
    16. London CA, Galli SJ, Yuuki T, Hu ZQ, Helfand SC, Geissler EN (1999): Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit. Experimental Hematology 27, 689-697. Go to original source... Go to PubMed...
    17. London CA, Hannah AL, Zadovoskaya R, Chien MB, KolliasBaker C, Rosenberg M, Downing S, Post G, Boucher J, Shenoy N, Mendel DB, McMahon G, Cherrington JM (2003): Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. Clinical Cancer Research 9, 2755-2768.
    18. London CA, Malpas PB, Wood-Follis SL, Boucher JF, Rusk AW, Rosenberg MP, Henry CJ, Mitchener KL, Klein MK, Hintermeister JG, Bergman PJ, Couto GC, Mauldin GN, Michels GM (2009): Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. Clinical Cancer Research 15, 3856-3865. Go to original source... Go to PubMed...
    19. Ma Y, Longley BJ, Wang X, Blount JL, Langley K, Caughey GH (1999): Clustering of activating mutations in c-KIT's juxtamembrane coding region in canine mast cell neoplasms. The Journal of Investigative Dermatology 112, 165-170. Go to original source... Go to PubMed...
    20. Nagata H, Okada T, Worobec A, Semere T, Metcalfe D (1997): C-kit mutation in a population of patients with mastocytosis. International Archives of Allergy and Immunology 113, 184-186. Go to original source... Go to PubMed...
    21. Nakano Y, Kobayashi T, Oshima F, Fukazawa E, Yamagami T, Shiraishi Y, Takanosu M (2014): Imatinib responsiveness in canine mast cell tumors carrying novel mutations of c-KIT exon 11. The Journal of Veterinary Medical Science 76, 545-548. Go to original source... Go to PubMed...
    22. Pryer NK, Lee LB, Zadovaskaya R, Yu X, Sukbuntherng J, Cherrington JM, London CA. (2003): Proof of target for SU11654 inhibition of KIT phosphorylation in canine mast cell tumors. Clinical Cancer Research 9, 5729-5734.
    23. Webster JD, Yuzbasiyan-Gurkan V, Kaneene JB, Miller R, Resau JH, Kiupel M (2006): The role of c-KIT in tumorigenesis: evaluation in canine cutaneous mast cell tumors. Neoplasia 8, 104-111. Go to original source... Go to PubMed...
    24. Yamada O, Kobayashi M, Sugisaki O, Ishii N, Ito K, Kuroki S, Sasaki Y, Isotani M, Ono K, Washizu T, Bonkobara M (2011): Imatinib elicited a favorable response in a dog with a mast cell tumor carrying a c-kit c.1523A>T mutation via suppression of constitutive KIT activation. Veterinary Immunology and Immunopathology 142, 101-106. Go to original source... Go to PubMed...
    25. Zavodovskaya R, Chien MB, London CA (2004): Use of kit internal tandem duplications to establish mast cell tumor clonality in 2 dogs. Journal of Veterinary Internal Medicine 18, 915-917. Go to original source...
    26. Zemke D, Yamini B, Yuzbasiyan-Gurkan V (2002): Mutations in the juxtamembrane domain of c-KIT are associated with higher grade mast cell tumors in dogs. Veterinary Pathology 39, 529-535. Go to original source... Go to PubMed...

    This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY NC 4.0), which permits non-comercial use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content